ANIXライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:44):

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases...

Stats
本日の出来高	74 919.00
平均出来高	123 090
時価総額	97.61M
EPS	$0 ( 2024-03-21 )
次の収益日	( $-0.110 ) 2024-06-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-9.00
ATR14	$0.0170 (0.56%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-09	Titterton Lewis H Jr	Buy	15 009	Common Stock
2024-03-15	Baskies Arnold M	Buy	10 000	Common Stock
2024-03-15	Kumar Amit	Buy	30 000	Common Stock
2024-01-12	Baskies Arnold M	Buy	25 000	Employee Stock Option (Right to Buy)
2024-01-12	Gottschalk Emily	Buy	25 000	Employee Stock Option (Right to Buy)

INSIDER POWER
61.03
Last 100 transactions
Buy: 11 656 359 \| Sell: 3 491 117

ボリューム相関

長: -0.01 (neutral)

短: 0.72 (moderate)

Signal:(39.641) Neutral

Anixa Biosciences Inc 相関

10 最も正の相関
TCON	0.862
AFMD	0.862
TECH	0.859
UTMD	0.856
TOUR	0.855
CDMO	0.855
HSIC	0.854
XRAY	0.854
ATXI	0.851
INFI	0.851

10 最も負の相関
TYHT	-0.869
NUVL	-0.866
TLND	-0.853
JUPW	-0.852
NAAC	-0.851
HERA	-0.851
HERAU	-0.85
SVFA	-0.85
CPAQ	-0.85
VPCB	-0.848

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Anixa Biosciences Inc 相関 - 通貨/商品

0.72
( moderate )

0.52
( weak )

0.00
( neutral )

0.10
( neutral )

0.75
( moderate )

-0.58
( weak negative )

Anixa Biosciences Inc 財務諸表

Annual	2023
収益:	$210 000
総利益:	$49 000.00 (23.33 %)
EPS:	$-0.320

FY	2023
収益:	$210 000
総利益:	$49 000.00 (23.33 %)
EPS:	$-0.320

FY	2022
収益:	$2.47B
総利益:	$2.47B (100.00 %)
EPS:	$-0.440

FY	2021
収益:	$512 500
総利益:	$127 498 (24.88 %)
EPS:	$-0.450

Financial Reports:

No articles found.

Anixa Biosciences Inc

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.